Abstract 10P
Background
There remains uncertainty regarding prognosis and treatment effect in small, node negative breast cancer. We described overall prognosis of small (<1cm), node (-), HER2 (+) breast cancer after curative surgery, and effect of adjuvant treatment. There remains uncertainty regarding prognosis and treatment effect in small, node negative breast cancer. We described overall prognosis of small (<1cm), node (-), HER2 (+) breast cancer after curative surgery, and effect of adjuvant treatment.
Methods
We identified patients who fulfilled inclusion criteria (curative surgery, <1cm, N0, and HER2(+) breast cancer) by medical chart review. We collected data of baseline characteristics, receptor status, surgical method, histologic type, histologic and nuclear grade, adjuvant treatment (chemotherapy, radiotherapy, endocrine therapy, and trastuzumab. We compared baseline characteristics between patients with or without adjuvant treatment (Chi-square), and the prognosis between them (Kaplan meier curve and log-rank test). SPSS version 18.0 was used for statistical analysis.
Results
A total of 429 patients (pT1a=205, pT1b=222) were identified. In patients with pT1a, only 1 patient experienced systemic recurrence and death. No difference was observed in DFS and OS between patients with adjuvant chemotherapy and/or adjuvant trastuzumab. In pT1b, HR(-) patients (N = 52), longer DFS was observed in patients who received adjuvant chemotherapy (p = 0.013). There was no difference in DFS according to trastuzumab treatment (p = 0.441). No difference was found according to adjuvant treatment in overall or HR(+) pT1b patients.
Conclusions
In conclusion, our result showed overall prognosis of small(<1cm), node (-), and HER2+ breast cancer and patients with pT1b and HR(-) patients can benefit from adjuvant chemotherapy. Subsequent study with large sample size is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract